Show simple item record

dc.contributor.authorHtar, Myint Tin Tin
dc.contributor.authorJackson, Sally
dc.contributor.authorBalmer, Paul
dc.contributor.authorSerra, Lidia Cristina
dc.contributor.authorVyse, Andrew
dc.contributor.authorSlack, Mary
dc.contributor.authorRiera-Montes, Margarita
dc.contributor.authorSwerdlow, David L
dc.contributor.authorFindlow, Jamie
dc.date.accessioned2021-01-04T00:56:03Z
dc.date.available2021-01-04T00:56:03Z
dc.date.issued2020
dc.identifier.issn1471-2458en_US
dc.identifier.doi10.1186/s12889-020-09946-1en_US
dc.identifier.urihttp://hdl.handle.net/10072/400562
dc.description.abstractBackground: Monovalent meningococcal C conjugate vaccine (MCCV) was introduced into the routine immunization program in many countries in Europe and worldwide following the emergence of meningococcal serogroup C (MenC) in the late 1990s. This systematic literature review summarizes the immediate and long-term impact and effectiveness of the different MCCV vaccination schedules and strategies employed. Methods: We conducted a systematic literature search for peer-reviewed, scientific publications in the databases of MEDLINE (via PubMed), LILACS, and SCIELO. We included studies from countries where MCCV have been introduced in routine vaccination programs and studies providing the impact and effectiveness of MCCV published between 1st January 2001 and 31st October 2017. Results: Forty studies were included in the review; 30 studies reporting impact and 17 reporting effectiveness covering 9 countries (UK, Spain, Italy, Canada, Brazil, Australia, Belgium, Germany and the Netherlands). Following MCCV introduction, significant and immediate reduction of MenC incidence was consistently observed in vaccine eligible ages in all countries with high vaccine uptake. The reduction in non-vaccine eligible ages (especially population > 65 years) through herd protection was generally observed 3–4 years following introduction. Vaccine effectiveness (VE) was mostly assessed through screening methods and ranged from 38 to 100%. The VE was generally highest during the first year after vaccination and waned over time. The VE was better maintained in countries employing catch-up campaigns in older children and adolescents, compared to routine infant only schedules. Conclusions: MCCV were highly effective, showing a substantial and sustained decrease in MenC invasive meningococcal disease. The epidemiology of meningococcal disease is in constant transition, and some vaccination programs now include adolescents and higher valent vaccines due to the recent increase in cases caused by serogroups not covered by MCCV. Continuous monitoring of meningococcal disease is essential to understand disease evolution in the setting of different vaccination programs.en_US
dc.description.peerreviewedYesen_US
dc.languageEnglishen_US
dc.language.isoeng
dc.publisherBMCen_US
dc.relation.ispartofpagefrom1890en_US
dc.relation.ispartofissue1en_US
dc.relation.ispartofjournalBMC Public Healthen_US
dc.relation.ispartofvolume20en_US
dc.subject.fieldofresearchPublic Health and Health Servicesen_US
dc.subject.fieldofresearchcode1117en_US
dc.subject.keywordsScience & Technologyen_US
dc.subject.keywordsLife Sciences & Biomedicineen_US
dc.subject.keywordsPublic, Environmental & Occupational Healthen_US
dc.subject.keywordsMeningococcal diseaseen_US
dc.subject.keywordsimmunizationen_US
dc.titleSystematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programsen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Articlesen_US
dcterms.bibliographicCitationHtar, MTT; Jackson, S; Balmer, P; Serra, LC; Vyse, A; Slack, M; Riera-Montes, M; Swerdlow, DL; Findlow, J, Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs, BMC Public Health, 2020, 20 (1), pp. 1890en_US
dcterms.dateAccepted2020-11-19
dcterms.licensehttp://creativecommons.org/licenses/by/4.0/en_US
dc.date.updated2021-01-03T23:35:13Z
dc.description.versionVersion of Record (VoR)en_US
gro.rights.copyright© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.en_US
gro.hasfulltextFull Text
gro.griffith.authorSlack, Mary P.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record